Kuyerekeza kwa malonda a Dulaglutide, Liraglutide ndi Semaglutide.

Chimphona chazamankhwala Lilly, kampani yaku America, ndi Novo Nordisk, kampani yaku Danish, adalengeza motsatizana za malonda awo mu 2020: Dulaglutide yakhala mankhwala a TOP1 GLP-1, ndikugulitsa $ 5.07Bn mu 2020, chaka- kuwonjezeka kwa chaka ndi 22.8%;liraglutide Kuyambira kulowa mu nthawi yotsika, malonda mu 2020 adatsika kuchokera ku $ 4.14Bn mpaka $ 3.93Bn, kuchepa kwa chaka ndi 5.1%;semaglutide inakula mofulumira kwambiri, ndipo malonda akufika $ 3.72Bn mu 2020, kuwonjezeka kwa chaka ndi chaka kwa 119.9%.

Lilly's dulaglutide (dzina la malonda Trulicity®) idakhazikitsidwa mu 2014 ndipo idakhala mankhwala osokoneza bongo omwe amagulitsidwa $5.07Bn m'zaka 6 zokha, kukhala katswiri wazogulitsa mankhwala a GLP-1.Chogulitsa chimodzi cha Novo Nordisk chatsalira kwakanthawi kumbuyo kwa Lilly.Liraglutide yake (dzina la malonda Victoza® ndi Saxenda®), yomwe idakhazikitsidwa mu 2009, idakhala katswiri wazogulitsa mankhwala a GLP-1, ndipo kugulitsa kwake kwakukulu mu 2017 kudafika $4.37Bn, ngakhale pali zisonyezo ziwiri za matenda a shuga amtundu wachiwiri komanso kunenepa kwambiri. , zidziwitso za 2020 zikuwonetsa kuti msika wa mankhwalawa walowa munthawi yotsika.Semaglutide yomweyi ya Novo Nordisk (mayina amalonda Ozempic® ndi Rybelsus®) yakula mofulumira ndipo yakula kukhala mankhwala ena a blockbuster omwe amagulitsa $ 3.72Bn m'zaka zitatu.Mankhwala awiri mlingo mitundu ya jekeseni ndi m`kamwa kukonzekera.

Malinga ndi malo, United States ndiye dziko logulitsa kwambiri la liraglutide, lomwe limawerengera pafupifupi 60% mu 2020, kutsika kwapachaka kwa 11.02%;ndiyenso kugwa kwachuma ku United States komwe kwadzetsa kutsika kwa msika wapadziko lonse wa liraglutide.Dera la EMEA (Europe, Middle East, Africa) lakula pang'onopang'ono, ndi CAGR ya 1.6% yokha m'zaka zisanu zapitazi;China ndiye msika womwe ukukula kwambiri, womwe ukugulitsidwa $182.50Mn mu 2020, ndi chiwonjezeko chapachaka cha 42.39%.Popeza semaglutide yakhala pamsika posachedwa, misika yonse ili pagawo lakukula mwachangu.United States ikadali msika waukulu kwambiri, womwe umawerengera 80.04% ya malonda mu 2020, kuwonjezeka kwa chaka ndi chaka kwa 106.08%;EMEA ili ndi gawo la 13.64% koma chaka ndi chaka chiwonjezeko cha 249.65% %.Semaglutide idakhazikitsidwa ku China mu 2020 ndikugulitsa $ 1.61Mn.Chithunzi 3 chikuwonetsa mkhalidwe wagawo wa dulaglutide.Monga msika waukulu kwambiri, United States ili ndi malonda okwana $3.836Bn, omwe amawerengera 75.69%, ndi chiwerengero cha kukula kwapachaka cha 79.18%.

Ma Patent a liraglutide (Victoza® ndi Saxenda®) atha ku China ndipo atsala pang'ono kutha ku US, Japan ndi Germany.Nkhondo ya Teva patent ndi Novo Nordisk yathetsedwa, ndipo Teva's generic version ipezeka mu 2023. Mylan adaperekanso ntchito ya ANDA ku FDA ya liraglutide ndi pempho la PIV.Pakutha kwapang'onopang'ono kwa ma patent apakati komanso chiwopsezo cha opanga mankhwala amtundu uliwonse, mankhwalawa alowa pang'onopang'ono m'nthawi yocheperako.Patent yaku US ya Trulicity® sidzatha mpaka 2027, pomwe ma Patent amayiko akulu aku Europe ndi Japan sadzatha mpaka 2029, ndipo chitetezo chachikulu cha patent ndichotalika kuposa cha liraglutide.Ma Patent a Semaglutide (Ozempic® ndi Rybelsus®) adzatha mu 2032 posachedwa, ndipo pali malo abwino oti msika ukule, koma nthawi yake ku China ndi 2026.